[{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Megapharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Megapharm","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Megapharm"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Tetris Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Tetris Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Tetris Pharma"},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tetris Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tetris Pharma \/ Arecor","highestDevelopmentStatusID":"15","companyTruncated":"Tetris Pharma \/ Arecor"},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tetris Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tetris Pharma \/ Arecor","highestDevelopmentStatusID":"15","companyTruncated":"Tetris Pharma \/ Arecor"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AmideBio","sponsor":"NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AmideBio \/ NIDDK","highestDevelopmentStatusID":"4","companyTruncated":"AmideBio \/ NIDDK"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Beta Bionics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Beta Bionics","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Beta Bionics"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Private Placement","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Antaros Medical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"||Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Antaros Medical","highestDevelopmentStatusID":"11","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Antaros Medical"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"South Texas Veterans Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Texas Health Science Center at San Antonio \/ South Texas Veterans Health Care System","highestDevelopmentStatusID":"6","companyTruncated":"University of Texas Health Science Center at San Antonio \/ South Texas Veterans Health Care System"},{"orgOrder":0,"company":"Abvance Therapeutics","sponsor":"T1D Exchange","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Abvance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abvance Therapeutics \/ T1D Exchange","highestDevelopmentStatusID":"6","companyTruncated":"Abvance Therapeutics \/ T1D Exchange"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Abvance Therapeutics","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Financing","leadProduct":"Insulin","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Abvance Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abvance Therapeutics \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"4","companyTruncated":"Abvance Therapeutics \/ Helmsley Charitable Trust"}]

Find Clinical Drug Pipeline Developments & Deals for Glucagon Recombinant

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Insulin Glulisine,Insulin aspart,Neutral Protamine Hagedorn Insulin,Glucagon,Glucose,Heparin Sodium

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          September 22, 2016

                          Lead Product(s) : Insulin Glulisine,Insulin aspart,Neutral Protamine Hagedorn Insulin,Glucagon,Glucose,Heparin Sodium

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The funding will support the pre-clinical development of ABV100, the Company’s initial proprietary insulin-glucagon combination candidate developing to treat diabetes.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          October 09, 2024

                          Lead Product(s) : Insulin,Glucagon

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Helmsley Charitable Trust

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The collaboration aims for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.

                          Product Name : Ogluo

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          June 05, 2024

                          Lead Product(s) : Glucagon,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Beta Bionics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Amphastar intends to use the proceeds for the payment of milestone payments in connection with the acquisition of Baqsimi (glucagon) nasal powder, used to treat very low blood sugar (severe hypoglycemia) in people with diabetes ages 4 years and above.

                          Product Name : Baqsimi

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          November 09, 2023

                          Lead Product(s) : Glucagon,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : $300.0 million

                          Deal Type : Private Placement

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Through the divestment, Amphastar will continue Lilly's mission to help more people benefit from Baqsimi (glucagon), the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.

                          Product Name : Baqsimi

                          Product Type : Peptide

                          Upfront Cash : $625.0 million

                          June 30, 2023

                          Lead Product(s) : Glucagon,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Amphastar Pharmaceuticals

                          Deal Size : $1,075.0 million

                          Deal Type : Divestment

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Through the divestment, Amphastar will continue Lilly's mission to help more people benefit from Baqsimi (glucagon), the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.

                          Product Name : Baqsimi

                          Product Type : Peptide

                          Upfront Cash : $625.0 million

                          April 24, 2023

                          Lead Product(s) : Glucagon,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Amphastar Pharmaceuticals

                          Deal Size : $1,075.0 million

                          Deal Type : Divestment

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Gvoke (glucagon) increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver.

                          Product Name : Gvoke

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          April 18, 2023

                          Lead Product(s) : Glucagon,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycaemia.

                          Product Name : Ogluo

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          December 12, 2022

                          Lead Product(s) : Glucagon,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Arecor

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : This two-year grant will allow AmideBio to select a long-acting soluble stable glucagon candidate and do the necessary work to support the filing of an Investigational New Drug (IND) application with the FDA at the end of the grant period.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          April 10, 2022

                          Lead Product(s) : Glucagon,Inapplicable

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : NIDDK

                          Deal Size : $2.7 million

                          Deal Type : Funding

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the terms of the proposed acquisition, Arecor Therapeutics has agreed to acquire Tetris Pharma and will continue to commercialize Ogluo in the UK and EEA. Gvoke® (US) /Ogluo® (EU), the first prescription, ready-to-use, pre-mixed, pre-measured glu...

                          Product Name : Ogluo

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          January 08, 2022

                          Lead Product(s) : Glucagon,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Arecor

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank